Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249454 | 1.00 | CA2 (0.40) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL591536 | 1.00 | CA2 (0.40) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL591538 | 1.00 | CA2 (0.40) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL591537 | 1.00 | CA2 (0.40) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL13305488 | 0.83 | CA2 (0.41) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL7154235 | 0.82 | CA2 (0.38) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL7156281 | 0.82 | CA2 (0.38) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL17888068 | 0.81 | CA2 (0.44) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL13305659 | 0.80 | CA2 (0.39) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 | |
| SCHEMBL14169666 | 0.79 | CA2 (0.41) | CA2TBXA2RTMEM97SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | UNIV KYOTO (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | UNIV KYOTO (JP) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278955-A1 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | VDR, CYP24A1, CYP2R1 | CA2 4061/4885TBXA2R 260/4885TMEM97 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.